Showing 12 out of 2273 items
- Prevention in FocusIntimate relationships can contribute to both vulnerability and resiliency to hepatitis C and HIV for women who inject drugs. We explore the issues and provide suggestions to help front-line workers…
- Prevention in FocusA complex range of interrelated and synergistic factors contribute to a higher risk of HIV infection for some individuals in certain populations disproportionately affected by the HIV epidemic in…
- Prevention in FocusAlthough there may be significant benefits to disclosing one’s HIV status to others, there may also be significant drawbacks. We review the evidence related to HIV disclosure to sexual partners,…
- Prevention in FocusIgnited by National HIV Testing Day in the United States, which occurs annually on June 27th, the AIDS Committee of Windsor holds an annual HIV Testing Day in their region. The 2015 campaign saw a…
- The following report previously appeared in CATIE News. We are putting it in this issue of TreatmentUpdate to underscore some of the issues related to care and ...
- Researchers in Australia conducted a study to understand the reasons why some HIV-positive people have either not started potent combination anti-HIV therapy ...
- Abacavir hypersensitivity screening can help to identify people who are at high risk for a serious adverse reaction to the anti-HIV drug abacavir (Ziagen, ABC) or any drug containing abacavir.
- This Q&A provides information on how Canadian immigration law and policy affect people living with HIV who wish to visit or live in Canada.
- Tropism testing lets your doctor know more about the type of HIV that is in your body. Results from this test will help you and your doctor decide which treatment to use.
- Early in the development of the Hepatitis C Ethnocultural Education, Outreach and Social Marketing Program, CATIE recognized that partnerships with immigrant-serving and settlement organizations…
- Translation is often a huge hurdle for organizations looking to serve new populations in their community.
- Kaletra is the brand name of treatment that contains two anti-HIV drugs called protease inhibitors - lopinavir and ritonavir.